General Information of Drug (ID: DM2QJ5A)

Drug Name
4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one Drug Info
Synonyms CHEMBL147398
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44364764
TTD Drug ID
DM2QJ5A

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glycine DMIOZ29 Allergic rhinitis CA08.0 Approved [2]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [3]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [4]
SPERMINE DMD4BFY N. A. N. A. Terminated [5]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [6]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [7]
DIZOCILPINE DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [8]
RPR-104632 DM9L50N N. A. N. A. Terminated [9]
L-698532 DMO9HM7 Neurological disorder 6B60 Terminated [10]
L-695902 DMT1DNS N. A. N. A. Terminated [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cycloserine DMT1I52 Bacterial infection 1A00-1C4Z Approved [11]
D-Serine DM3YH4I N. A. N. A. Phase 4 [12]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [13]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [3]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [4]
SPERMINE DMD4BFY N. A. N. A. Terminated [5]
L-689560 DMCVY4U Neurodegenerative disorder 8A20-8A23 Terminated [14]
L-698544 DMLRBN1 Alzheimer disease 8A20 Terminated [7]
DIZOCILPINE DMMGYXR Cerebrovascular ischaemia 8B1Z Terminated [8]
RPR-104632 DM9L50N N. A. N. A. Terminated [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alpha 1-PI DMXC1K9 Alpha-1 antitrypsin deficiency 5C5A Approved [15]
ELIPRODIL DMIOGZM Multiple sclerosis 8A40 Phase 2 [13]
CP-101,606 DMIU19E Parkinson disease 8A00.0 Phase 2 [16]
CERC-301 DMSABRI Major depressive disorder 6A70.3 Phase 2 [17]
RGH-896 DMCHZAN Peripheral neuropathy 8C0Z Phase 2 [18]
MIJ821 DMN45RI Major depressive disorder 6A70.3 Phase 2 [19]
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [3]
Neu-2000 DMNJTLC Cardiac arrest MC82 Phase 1 [20]
EVT100 DMAKWQD Major depressive disorder 6A70.3 Phase 1 [21]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [4]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor ionotropic NMDA 1 (NMDAR1) TTLD29N NMDZ1_HUMAN Inhibitor [1]
Glutamate receptor ionotropic NMDA 2A (NMDAR2A) TTKJEMQ NMDE1_HUMAN Inhibitor [1]
Glutamate receptor ionotropic NMDA 2B (NMDAR2B) TTN9D8E NMDE2_HUMAN Inhibitor [1]

References

1 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996).
2 Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78.
3 Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65.
4 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7.
5 Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456).
7 Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993).
8 Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9.
9 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
10 Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71.
11 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
12 Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
13 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455).
15 NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250.
16 NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8.
17 Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8.
18 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
19 Clinical pipeline report, company report or official report of Cadent Therapeutics.
20 Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56.
21 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)